Jin Young Chung

Sr. Manager at Cenyx Biotech, Inc.

Presenter

Cenyx Biotech Inc. is a pioneering nanomedicine company developing first-in-human nanozyme therapeutics to address acute and chronic inflammatory diseases with high unmet medical needs. Our lead candidate, CX213, has received FDA IND approval and orphan drug designation (ODD) for subarachnoid hemorrhage (SAH)-induced inflammation, a life-threatening condition with no approved medicinal therapy. As a first-in-class nanozyme therapeutic, CX213 targets severe oxidative stress and inflammation, offering a breakthrough approach in emergency care. Phase 1 clinical trials are set to begin in 2Q 2025 in the US, with an expedited market entry strategy utilizing Breakthrough Therapy Designation, Fast Track Designation, and Accelerated Approval pathways, aiming for commercial launch in major markets by 2028. Our second pipeline, CX301 is advancing toward the clinic, with IND submission and approval expected in 2Q 2025. CX301 is being developed for acute kidney injury (AKI), a high-market-potential indication with limited treatment options and a growing global burden, particularly in critical care and hospitalized patients. Backed by over a decade of nanozyme research, Cenyx’s team brings 50+ years of combined expertise in cerium oxide nanoparticles, with 10+ patents and 20+ peer-reviewed publications in leading journals. Our proprietary INNOSURFACE platform enables the development of next-generation anti-inflammatory nanozymes across multiple administration routes, including parenteral (IV), enteric, dermal, and conjugate-based delivery. We have secured multiple national grants and established a GMP-compliant in-house manufacturing facility, ensuring a streamlined pathway from clinical development to commercialization. Cenyx is actively pursuing strategic partnerships to accelerate clinical progress and global commercialization. Our nanozyme pipeline presents a unique opportunity for biopharma companies looking to pioneer next-generation anti-inflammatory therapeutics.